Study of the Oral Treatment MTR-601 in Cervical Dystonia

NCT ID: NCT06830642

Last Updated: 2025-12-12

Basic Information

• Recruitment Status: SUSPENDED
• Clinical Phase: PHASE2
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-02-28
• Study Completion Date: 2026-08-03

Brief Summary

Study MTR-601-201 is an 8-week, randomized, placebo-controlled study to examine the safety, tolerability, and efficacy of MTR-601 in participants with cervical dystonia.

Detailed Description

Study MTR-601-201 is an 8-week, randomized, placebo-controlled study to examine the safety, tolerability, and efficacy of MTR-601 in participants with cervical dystonia.

Participants will be randomized (1:1) to receive either MTR-601 or matching placebo every day for 4 weeks, after which all participants will be followed for an additional 2 weeks through study treatment washout. The Investigator and Participant will be blinded to the assigned arm. Treatment will be administered via capsules and matching placebo capsules. The total sample size will be approximately 80 participants.

The study will be divided into 3 periods: Screening, Treatment and Follow up.

An initial screening assessment (V1) will occur between Day -90 and Day -2, where individuals will undergo informed consent and have their preliminary eligibility reviewed. Individuals who are found to be eligible will be instructed to not receive their next scheduled botulinum toxin treatment prior to entry into the study.

A full Screening visit (V2) will occur between Day -14 and -1.

Individuals who are confirmed to be eligible after V2, including having not received botulinum toxin treatment for ≥3 months (≥6 months for daxibotulinum ToxinA), will return to clinic on Day 1 for randomization and initiation of study treatment (V3). At this visit individuals will be randomized into the study and receive either MTR-601 or matching placebo to take for the duration of the study and will be discharged home.

Individuals will take the first dose and subsequent doses of study treatment once daily while at home, with weekly visits during the treatment period to assess safety, tolerability and efficacy.

At Day 36 and thereafter, participants may resume treatment with botulinum toxin or daxibotulinum toxinA.

Individuals will return to the clinic 14 days after completion of treatment (Day 42) for the end of study visit (V8) where final safety assessments will be performed. Individuals will then be discontinued from the study.

Conditions

Cervical Dystonia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

MTR-601

Group Type: EXPERIMENTAL

MTR-601

Intervention Type: DRUG

Capsule

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Capsule

Interventions

MTR-601

Capsule

Intervention Type: DRUG

Placebo

Capsule

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Willing to adhere to study procedures and provide written informed consent prior to the start of any study procedures.

2. Confirmed clinical diagnosis of cervical dystonia with the following:

• Treatment with botulinum toxin injections (any type) on a stable dosing regimen for ≥ 2 consecutive doses at V2 or a history of botulinum toxin injections within the last 5 years which were discontinued for reasons other than lack of efficacy.
• 3 months (90 days) since botulinum toxin injection (≥6 months (180 days) for daxibotulinum toxinA) at V3
• TWSTRS total score ≥ 20 with the following sub scores at V2:
• Severity ≥ 15
• Disability ≥ 3
• Pain score ≥ 1)
• Willingness to not use botulinum toxin for duration of their study participation

3. Adults 18-80 years of age at the time of consent.

4. Weight ≥40 kg and body mass index (BMI) ≤35 kg/m2.

5. Agree to practice highly effective birth control starting at screening and continuing for 30 days (females) or 90 days (males) after study treatment ends.

• For females any of the following (no donation of eggs/ova is allowed):
• Abstinence from heterosexual intercourse.
• Postmenopausal: absence of menses ≥ 12 months (without an alternative medical condition) and FSH ≥ 40 mIU/mL at screening.
• Surgically sterile: bilateral oophorectomy, salpingectomy, tubal ligation, or hysterectomy ≥180 days prior to screening.
• Contraceptive implant or intrauterine device.
• For males any of the following:
• Abstinence from heterosexual intercourse.
• Male condom with spermicide or male condom with vaginal spermicide (gel, foam, or suppository).
• Surgically sterile: post vasectomy or bilateral orchiectomy ≥180 days prior to screening.
• No donation of sperm is allowed

Participants who meet ANY of the following criteria will be excluded from participation in the study:

1. History of, or physical examination findings indicating, clinically significant endocrine, neurological, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or muscle abnormalities or diseases that, in the opinion of the Investigator, renders the participant unsuitable for the study.

2. History of any of the following:

• Cervical dystonia due to trauma
• Chronic contractures in the head and neck musculature
• Generalized dystonia of any type
• Myasthenia gravis (MG) or amyotrophic lateral sclerosis (ALS)

3. Use of the following treatment for cervical dystonia:

• Botulinum toxin (of any type) within 3 months (90 days) (6 months (180 days) for daxibotulinum toxinA) at Baseline (V3)
• Baclofen by intrathecal pump within 6 months (180 days) months at Baseline (V3)
• Any previous history of deep brain stimulation or surgery intended to treat or correct cervical dystonia (e.g. myectomy)
• Other treatments for cervical dystonia (anti-cholinergic, muscle relaxants such as flexeril or oral baclofen, or benzodiazepines) are allowed if the dose has been stable for ≥3 months (90 days).

4. Use of the following medications within 2 weeks prior to V3:

• CYP3A inhibitors, inducers and substrates.
• BCRP substrates: rosuvastatin, sulfasalazine

5. Use of the following food or beverages which might interact with MTR-601 within the last week prior to V3:

• Grapefruit juice or food products containing Seville orange extract (e.g. British orange marmalade, bitter orange liqueurs)

6. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, that, in the opinion of the Investigator, renders the participant unsuitable for the study.

7. Active neoplastic disease or history of any neoplastic disease within 5 years of screening (except for basal or squamous cell carcinoma of the skin or carcinoma in situ that has been definitively treated with standard of care).

8. Active infection (e.g., sepsis, pneumonia, abscess) or a serious infection (e.g., resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks prior to dosing.

9. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed).

10. Any of the following at screening (V2) (if any of these conditions are found on initial ECG, a repeat

ECG is allowed in consultation with the medical monitor):

• QT interval corrected for heart rate using Fridericia's formula (QTcF), QRS duration, PR interval outside of normal limits confirmed by repeat measurement, unless deemed non-clinically significant by PI and agreed by Medical Monitor
• Findings which would make QTc measurements difficult or QTc data uninterpretable
• History of additional risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome)

11. Positive urine alcohol screen or positive urine drug screen (including amphetamines, cocaine, opiates, or barbiturates), at screening (V2).

• Benzodiazepines will be allowed if prescribed for cervical dystonia, and on a stable dose for ≥3 months (90 days) at screening (V2).
• Cannabis use and cannabinoid positive drug screen is allowed.
• Smoking and cotinine positive screen is allowed.

12. Positive hepatitis panel and/or positive human immunodeficiency virus test at screening (V2).

13. Any of the following laboratory values at screening or on Day -1, as confirmed by 1 repeat if necessary:

• Hemoglobin <11 g/dL for females, and <12 g/dL for males
• Absolute neutrophil count (ANC) <1.5 × 109

/L (<1500/μL).

• Aspartate aminotransferase (AST), alanine aminotransferase (ALT), gammaglutamyl transferase (GGT), alkaline phosphatase (ALP), or total bilirubin >1.5 × upper limit of normal (ULN) at screening or on Day -1, confirmed by 1 repeat if necessary.

14. Participation in a clinical study involving administration of an investigational drug (new chemical entity) or medical device within the last 90 days or 5 half-lives of the investigational medication, whichever is longer, prior to dosing.

15. Receipt of blood products within 2 months prior to Day -1.

16. Donation of blood (>400 mL) or comparable blood loss (>350 mL) from 3 months prior to screening, plasma donation from 2 weeks prior to screening, or platelets donation from 6 weeks prior to screening.

17. Participants who, in the opinion of the Investigator (or designee; including input from participants' general practitioner, as applicable), should not participate in this study.

18. Participants who are investigational site staff members or directly involved in the conduct of the study and their family members or participants who are employed by the Sponsor.

19. Pregnant or nursing (lactating) females

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Motric Bio

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Arizona Neuroscience Research, LLC

Phoenix, Arizona, United States

The Parkinson's and Movement Disorder Institute

Fountain Valley, California, United States

Keck Medicine of University of Southern California

Los Angeles, California, United States

CenExel Rocky Mountain Clinical Research

Englewood, Colorado, United States

Neurology One

Orlando, Florida, United States

University of South Florida

Tampa, Florida, United States

Emory University

Atlanta, Georgia, United States

Rush University Medical Center

Chicago, Illinois, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Michigan State University, Department of Neurology

East Lansing, Michigan, United States

Quest Research Institute

Farmington Hills, Michigan, United States

University of New Mexico, The Nene and Jamie Koch Comprehensive Movement Disorder Clinic

Albuquerque, New Mexico, United States

Albany Medical Center Neurosciences Institute

Albany, New York, United States

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Vanderbilt Neurology, The Vanderbilt Clinic

Nashville, Tennessee, United States

Kingfisher Cooperative, LLC

Spokane, Washington, United States

West Virginia University Medicine

Morgantown, West Virginia, United States

Countries

United States

Other Identifiers

MTR-601-201

Identifier Type: -

Identifier Source: org_study_id